Mather Group LLC. Sells 601 Shares of Moderna, Inc. (NASDAQ:MRNA)

Posted by on Jun 18th, 2023

Mather Group LLC. lessened its holdings in Moderna, Inc. (NASDAQ:MRNA – Get Rating) by 8.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,599 shares of the company’s stock after selling 601 shares during the quarter. Mather Group LLC.’s holdings in Moderna were worth $1,185,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Boenning & Scattergood Inc. acquired a new position in shares of Moderna during the 4th quarter worth approximately $307,000. Brown Advisory Inc. grew its position in Moderna by 17.8% during the third quarter. Brown Advisory Inc. now owns 3,183 shares of the company’s stock worth $376,000 after buying an additional 481 shares in the last quarter. Ascendant Capital Management LLC bought a new position in Moderna during the 4th quarter worth $359,000. Patton Fund Management Inc. acquired a new position in Moderna in the 4th quarter valued at $207,000. Finally, Toroso Investments LLC raised its holdings in Moderna by 8.2% in the 3rd quarter. Toroso Investments LLC now owns 30,432 shares of the company’s stock valued at $3,599,000 after acquiring an additional 2,319 shares in the last quarter. 63.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. TD Cowen upgraded Moderna from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $150.00 to $180.00 in a research report on Monday, March 13th. JPMorgan Chase & Co. boosted their target price on shares of Moderna from $127.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, April 10th. SVB Leerink downgraded shares of Moderna from a “market perform” rating to an “underperform” rating and cut their price target for the stock from $111.00 to $93.00 in a report on Friday, February 24th. Royal Bank of Canada started coverage on shares of Moderna in a research note on Wednesday, March 1st. They issued an “outperform” rating and a $200.00 price objective on the stock. Finally, Guggenheim began coverage on Moderna in a research note on Tuesday, April 25th. They set a “neutral” rating for the company. Two research analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $179.13.

Insider Transactions at Moderna

In other Moderna news, CEO Stephane Bancel sold 40,000 shares of the stock in a transaction that occurred on Thursday, March 30th. The shares were sold at an average price of $148.63, for a total transaction of $5,945,200.00. Following the completion of the sale, the chief executive officer now owns 5,411,946 shares of the company’s stock, valued at approximately $804,377,533.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Moderna news, President Stephen Hoge sold 1,181 shares of the business’s stock in a transaction that occurred on Tuesday, May 30th. The stock was sold at an average price of $124.95, for a total value of $147,565.95. Following the transaction, the president now directly owns 1,631,961 shares of the company’s stock, valued at $203,913,526.95. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Stephane Bancel sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 30th. The stock was sold at an average price of $148.63, for a total transaction of $5,945,200.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares of the company’s stock, valued at approximately $804,377,533.98. The disclosure for this sale can be found here. Insiders sold 446,850 shares of company stock worth $61,918,563 over the last ninety days. 15.70% of the stock is owned by insiders.

Moderna Trading Down 1.0 %

MRNA opened at $128.73 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.46 and a quick ratio of 3.26. Moderna, Inc. has a fifty-two week low of $115.03 and a fifty-two week high of $217.25. The company’s 50 day moving average price is $133.52 and its two-hundred day moving average price is $157.72. The firm has a market capitalization of $49.07 billion, a price-to-earnings ratio of 11.13 and a beta of 1.70.

Moderna (NASDAQ:MRNA – Get Rating) last posted its quarterly earnings data on Thursday, May 4th. The company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.77) by $1.96. The business had revenue of $1.86 billion during the quarter, compared to the consensus estimate of $1.17 billion. Moderna had a return on equity of 25.87% and a net margin of 31.77%. Moderna’s quarterly revenue was down 69.3% on a year-over-year basis. During the same period in the prior year, the business posted $8.58 earnings per share. As a group, research analysts predict that Moderna, Inc. will post -3.16 earnings per share for the current year.

Moderna Profile

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Featured Stories

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.